{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T23:54:57Z","timestamp":1789343697389,"version":"build-2803163510"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To evaluate the effects of different types of nucleos(t)ide analogs on the survival rate of patients with hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC) after radical resection through a network meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, the Cochrane Library, and CNKI databases were searched up to 6 March 2024. The NOS was used to assess the risk of bias in cohort studies, while the ROB tool in Review Manager was employed for randomized controlled trials. Data on overall survival (OS) and recurrence-free survival (RFS) were extracted from the literature to pool hazard ratios (HRs) and corresponding 95% CrIs. Meta-analysis was performed via R.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>24 studies involving 9,787 HBV-HCC patients were included. Compared with the control group, antiviral therapies using telbivudine (HR [95% CrI] = 0.23 [0.12,0.44]), tenofovir disoproxil fumarate (HR [95% CrI] = 0.40 [0.30,0.52]), lamivudine (HR [95% CrI] = 0.50 [0.34, 0.75]), adefovir (HR [95% CrI] = 0.55 [0.38,0.79]), and entecavir (HR [95% CrI] = 0.55 [0.43,0.71]) significantly improved OS. Among these, telbivudine (98.22%) and tenofovir disoproxil fumarate (76.12%) demonstrated superior effects in improving OS. Compared with the control group, antiviral therapies using telbivudine (HR [95% CrI] = 0.45 [0.28,0.70]), tenofovir disoproxil fumarate (HR [95% CrI] = 0.52 [0.44,0.62]), entecavir (HR [95% CrI] = 0.65 [0.55,0.77]),adefovir (HR [95% CrI] = 0.79 [0.65,0.94]),and lamivudine (HR [95% CrI] = 0.82 [0.71, 0.94]) significantly improved RFS. Telbivudine (SUCRA, 93.22%) and tenofovir disoproxil fumarate (SUCRA, 85.37%) exhibited superior effects in improving RFS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>When compared to other nucleos(t)ide analogs, telbivudine and tenofovir disoproxil fumarate exhibited the most notable effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review<\/jats:title>\n                    <jats:p>Identifier CRD42024612794.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1647888","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T05:10:45Z","timestamp":1763097045000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Different nucleos(t)ide analogs in resected hepatitis B virus-associated hepatocellular carcinoma: a systematic review"],"prefix":"10.3389","volume":"16","author":[{"given":"Hongquan","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengxia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songhui","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1128\/jvi.01796-09","article-title":"Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains","volume":"84","author":"Amini-Bavil-Olyaee","year":"2010","journal-title":"J. Virol."},{"key":"B2","first-page":"97","article-title":"Role of antiviral treatment in hepatitis related liver cancer recurrence","volume":"35","author":"Chen","year":"2015","journal-title":"Chin. J. Biochem. Pharm."},{"key":"B3","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.2147\/ott.S150281","article-title":"The effect of antiviral therapy on patients with hepatitis B virus-related hepatocellular carcinoma after curative resection: a systematic review and meta-analysis","volume":"10","author":"Chen","year":"2017","journal-title":"Onco Targets Ther."},{"key":"B4","first-page":"882","article-title":"A study of antiviral therapy in prevention of tumor recurrence after radical liver resection of hepatocellular carcinoma with high load of hepatitis B virus DNA","volume":"31","author":"Cheng","year":"2011","journal-title":"J. Nanjing Medicial Univ."},{"key":"B5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3969\/j.issn.1002-2600.2023.05.008","article-title":"Analysis of chronic hepatitis B disease progression with low ALT level by HBcrAg expression level combined with CD4+CD25+regulatory T cells","volume":"45","author":"Cheng","year":"2023","journal-title":"Fujian Med. J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/hep.31289","article-title":"Tenofovir Versus entecavir on recurrence of hepatitis B virus\u2013related hepatocellular carcinoma after surgical resection","volume":"73","author":"Choi","year":"2021","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3969\/j.issn.1001-5256.2014.07.021","article-title":"Efficacy of antiviral therapy in hepatocellular carcinoma patients with high HBV DNA levels after radical resection","volume":"30","author":"Ding","year":"2014","journal-title":"J. Clin. Hepatology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3969\/j.issn.1674-4659.2012.07.1079","article-title":"Influence of antiviral therapy on the clinical postoperative prognosis of primary liver cancer with positive HBV DNA","volume":"19","author":"Fang","year":"2012","journal-title":"Clin. Med. & Eng."},{"key":"B9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.13898\/j.cnki.issn.1000-2200.2019.03.015","article-title":"Effect of the nucleoside analogues in the treatment of chronic hepatitis B and its correlation with regulatory T cells of peripheral blood","volume":"44","author":"He","year":"2019","journal-title":"J. Bengbu Med. Coll."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e14386","DOI":"10.1097\/MD.0000000000014386","article-title":"The different effects of adefovir dipivoxil and telbivudine on the prognosis of hepatitis b virus-related hepatocellular carcinoma patients after curative resection","volume":"98","author":"He","year":"2019","journal-title":"Med. Baltim."},{"key":"B11","doi-asserted-by":"publisher","first-page":"115741","DOI":"10.1016\/j.bcp.2023.115741","article-title":"Nucleoside-based anticancer drugs: mechanism of action and drug resistance","volume":"215","author":"Hruba","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3390\/v14040656","article-title":"Tenofovir vs. Entecavir on outcomes of Hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation","volume":"14","author":"Hu","year":"2022","journal-title":"Viruses"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1053\/j.gastro.2011.06.048","article-title":"Hepatitis B virus core promoter mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21","volume":"141","author":"Huang","year":"2011","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1245\/s10434-012-2803-7","article-title":"Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load","volume":"20","author":"Huang","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/sla.0000000000000858","article-title":"Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial","volume":"261","author":"Huang","year":"2015","journal-title":"Ann. Surg."},{"key":"B16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2147\/jhc.S307962","article-title":"The mechanisms of HBV-induced hepatocellular carcinoma","volume":"8","author":"Jiang","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/apt.17438","article-title":"Entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy","volume":"57","author":"Kao","year":"2023","journal-title":"Alimentary Pharmacol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"158","DOI":"10.7497\/j.issn.2095-3941.2013.03.006","article-title":"Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy","volume":"10","author":"Ke","year":"2013","journal-title":"Cancer Biol. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"939","DOI":"10.5009\/gnl15527","article-title":"Lamivudine versus Entecavir for newly diagnosed hepatitis B virus-related hepatocellular carcinoma","volume":"10","author":"Kim","year":"2016","journal-title":"Gut Liver"},{"key":"B20","doi-asserted-by":"publisher","first-page":"S84-S101","DOI":"10.1016\/j.jhep.2016.02.021","article-title":"Mechanisms of HBV-induced hepatocellular carcinoma","volume":"64","author":"Levrero","year":"2016","journal-title":"J. Hepatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/17474124.2020.1784727","article-title":"Perioperative antiviral therapy improves the prognosis of HBV DNA-negative patients with HBV-related hepatocellular carcinoma","volume":"14","author":"Li","year":"2020","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"795","DOI":"10.19803\/j.1672-8629.2021.08.22","article-title":"Research progress on nucleos(t)ide analogues resistance mechanism and mutation sites","volume":"18","author":"Li","year":"2021","journal-title":"Chin. J. Pharmacovigil."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e2340353","DOI":"10.1001\/jamanetworkopen.2023.40353","article-title":"Tenofovir vs Entecavir among patients with HBV-Related HCC after resection","volume":"6","author":"Li","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3969\/j.issn.1674-3806.2016.02.14","article-title":"Clinical study of entecavir on treating hepatitis B related hepatic carcinoma after radical operation","volume":"9","author":"Lin","year":"2016","journal-title":"Chin. J. New Clin. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1097\/js9.0000000000000554","article-title":"Tenofovir versus entecavir on the prognosis of hepatitis B-related hepatocellular carcinoma after surgical resection: a randomised controlled trial","volume":"109","author":"Linye","year":"2023","journal-title":"Int. J. Surg."},{"key":"B27","doi-asserted-by":"publisher","first-page":"105058","DOI":"10.1016\/j.antiviral.2021.105058","article-title":"Investigation of multidrug-resistance mutations of hepatitis B virus (HBV) in a large cohort of chronic HBV-infected patients with treatment of nucleoside\/nucleotide analogs","volume":"189","author":"Liu","year":"2021","journal-title":"Antivir. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2288-14-45","article-title":"Newcastle-ottawa scale: comparing reviewers' to authors' assessments","volume":"14","author":"Lo","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/jvh.13236","article-title":"Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy\/ablation","volume":"27","author":"Qi","year":"2020","journal-title":"J. Viral Hepat."},{"key":"B30","doi-asserted-by":"publisher","first-page":"8421","DOI":"10.1002\/cam4.4348","article-title":"Comparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection: a multicenter study","volume":"10","author":"Qi","year":"2021","journal-title":"Cancer Med."},{"key":"B31","first-page":"349","article-title":"Influence of antiviral therapy on postoperative liver function and prognosis of HBV DNA-negative patients with HBV related hepatocellular carcinoma","volume":"25","author":"Ren","year":"2018","journal-title":"Chin. J. Cancer Prev. Treat."},{"key":"B32","doi-asserted-by":"publisher","first-page":"13596535211067605","DOI":"10.1177\/13596535211067605","article-title":"Adefovir for lamivudine-resistant hepatitis B","volume":"27","author":"Roediger","year":"2022","journal-title":"Antivir. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e7608","DOI":"10.1097\/md.0000000000007608","article-title":"Intermediate-stage hepatocellular carcinoma patients with a high HBV-DNA load may benefit from postoperative anti-hepatitis B virus therapy","volume":"96","author":"Rui","year":"2017","journal-title":"Med. Baltim."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/jvh.12911","article-title":"The prognostic significance of serum HBeAg on the recurrence and long-term survival after hepatectomy for hepatocellular carcinoma: a propensity score matching analysis","volume":"25","author":"Shen","year":"2018","journal-title":"J. Viral Hepat."},{"key":"B35","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/CM9.0000000000001864","article-title":"Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy","volume":"135","author":"Shen","year":"2022","journal-title":"Chin. Med. J. Engl."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1111\/j.1440-1746.2012.07145.x","article-title":"Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma","volume":"27","author":"Shin","year":"2012","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"7149","DOI":"10.3748\/wjg.v18.i48.7149","article-title":"Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues","volume":"18","author":"Song","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e66457","DOI":"10.1371\/journal.pone.0066457","article-title":"The influence of hepatitis B viral load and Pre-S deletion mutations on post-operative recurrence of hepatocellular carcinoma and the tertiary preventive effects by anti-viral therapy","volume":"8","author":"Su","year":"2013","journal-title":"PLoS One"},{"key":"B39","doi-asserted-by":"publisher","first-page":"334","DOI":"10.21037\/atm.2016.09.19","article-title":"Treatment for hepatitis B in patients with drug resistance","volume":"4","author":"Tacke","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3259833","DOI":"10.1155\/2021\/3259833","article-title":"Clinical features and resistance to Entecavir monotherapy of patients with hepatitis B","volume":"2021","author":"Takayama","year":"2021","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00535-022-01855-x","article-title":"Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection","volume":"57","author":"Wang","year":"2022","journal-title":"J. Gastroenterol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3969\/j.issn.1006-9488.2023.06.013","article-title":"Effect of preoperative antiviral therapy on viral reactivation and liver function in patients with HBV-DNA negative hepatocellular carcinoma","volume":"29","author":"Wang","year":"2023","journal-title":"Fertil. Health"},{"key":"B43","first-page":"2576","article-title":"Effect of radical resection combined with antiviral therapy in patients with hepatitis B virus-associated hepatocellular carcinoma and prognostic analysis","volume":"25","author":"Xiao","year":"2021","journal-title":"J. BUON"},{"key":"B44","doi-asserted-by":"publisher","first-page":"157","DOI":"10.14163\/j.cnki.11-5547\/r.2021.24.055","article-title":"Analyzing the effects of interferon and nucleotide analogs on peripheral blood regulatory T cell levels in patients with chronic hepatitis B","volume":"16","author":"Xu","year":"2021","journal-title":"China Pract. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12957-019-1577-9","article-title":"Antiviral therapy predicts the outcomes following resection of hepatocellular carcinoma in patients negative for HBV DNA: a propensity score matching analysis","volume":"17","author":"Xu","year":"2019","journal-title":"World J. Surg. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1038\/s41598-020-59775-w","article-title":"Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine","volume":"10","author":"Yasutake","year":"2020","journal-title":"Sci. Rep."},{"key":"B47","volume-title":"Comparative analysis of the distribution characteristics of CD8\u223c+CD28\u223c- and CD4\u223c+CD25\u223c(high) regulatory T cells in peripheral blood of hepatitis B patients and their clinical significance","author":"Yu","year":"2018"},{"key":"B48","first-page":"946","article-title":"The role of antiviral treatment in HBV related liver cancer recurrence","volume":"15","author":"Zhang","year":"2015","journal-title":"J. Trop. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1097\/meg.0000000000000153","article-title":"Higher efficacy of antiviral therapy after major hepatectomy in patients with hepatitis B virus-related hepatocellular carcinoma of less than 3 cm","volume":"26","author":"Zhang","year":"2014","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3969\/j.issn.1674-6929.2019.05.020","article-title":"Progress in research on hepatitis B virus resistance","volume":"11","author":"Zhang","year":"2019","journal-title":"J. Mol. Diagnosis Ther."},{"key":"B51","doi-asserted-by":"publisher","first-page":"6897","DOI":"10.2147\/ott.S120062","article-title":"Adefovir dipivoxil is less expensive than lamivudine and associated with similar prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after radical resection","volume":"9","author":"Zhong","year":"2016","journal-title":"Onco Targets Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1647888\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T05:10:54Z","timestamp":1763097054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1647888\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":51,"alternative-id":["10.3389\/fphar.2025.1647888"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1647888","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"article-number":"1647888"}}